Spironolactone in chronic hemodialysis patients improves cardiac function
Joint Authors
Shahidi, Shahrzad
Taheri, Shahram
Mortazavi, Mojhgan
Pourmoghadas, Ali
Garakyaraghi, Muhammad
Seirafian, Shiva
Eshaghian, Afrooz
Ghassami, Maryam
Source
Saudi Journal of Kidney Diseases and Transplantation
Issue
Vol. 20, Issue 3 (30 Jun. 2009), pp.392-397, 6 p.
Publisher
Saudi Center for Organ Transplantation
Publication Date
2009-06-30
Country of Publication
Saudi Arabia
No. of Pages
6
Main Subjects
Topics
- Patients
- Cardiovascular system
- Diseases
- Heart failure
- Therapeutics
- Hemodialysis
- Complications(Medicine)
- Spironolactone
Abstract EN
We performed this study to assess whether low dose spironolactone could be administered in hemodialysis (HD) patients with moderate to severe heart failure to improve cardiovascular function and reduce hospitalization without inducing hyperkalemia.
We enrolled 16 chronic HD patients with moderate to severe heart failure and left ventricle ejection fraction : 5 45%.
In a double blinded randomized placebo controlled study, one group of 8 patients received 25 mg of spironolactone after each dialysis session within six months, and the rest received a placebo.
Echocardiography was performed on all the patients to assess ejection fraction and left ventricular mass during 12 hours after completion of hemodialysis at the beginning and the end of study.
Serum potassium was measured predialysis every 4 weeks.
The mean ejection fraction increased significantly more in spironolactone group during the study period than in the placebo group (6.2 ± 1.64 vs.
0.83 ± 4.9, P = 0.046).
The mean left ventricular mass decreased in the spironolactone group, but increased significantly in the placebo group during the period (-8.4 ± 4.72 vs.
3 ± 7.97.
95%, P = 0.021).
The incidence of hyperkalemia was not significantly increased in the study or controlled groups.
In conclusion, we found in this study that administration of spironolactone in chronic HD patients with moderate to severe heart failure substantially improved their cardiac function and decreases left ventricular mass without development of significant hyperkalemia.
American Psychological Association (APA)
Taheri, Shahram& Mortazavi, Mojhgan& Shahidi, Shahrzad& Pourmoghadas, Ali& Garakyaraghi, Muhammad& Seirafian, Shiva…[et al.]. 2009. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi Journal of Kidney Diseases and Transplantation،Vol. 20, no. 3, pp.392-397.
https://search.emarefa.net/detail/BIM-36688
Modern Language Association (MLA)
Taheri, Shahram…[et al.]. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi Journal of Kidney Diseases and Transplantation Vol. 20, no. 3 (Sep. 2009), pp.392-397.
https://search.emarefa.net/detail/BIM-36688
American Medical Association (AMA)
Taheri, Shahram& Mortazavi, Mojhgan& Shahidi, Shahrzad& Pourmoghadas, Ali& Garakyaraghi, Muhammad& Seirafian, Shiva…[et al.]. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi Journal of Kidney Diseases and Transplantation. 2009. Vol. 20, no. 3, pp.392-397.
https://search.emarefa.net/detail/BIM-36688
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 396-397
Record ID
BIM-36688